Latest Regulus Therapeutics Stories
Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early
-- Collaboration Combines Isis' RNA-Targeted Technology With Expertise of Janssen in Autoimmune Disorders and Therapeutic Formulation -- CARLSBAD, Calif., Jan.
Recognized Industry Leader in Pharmaceutical Development Claremont, CA (PRWEB) December 16, 2014 Synedgen is pleased to announce the appointment of Paul
LA JOLLA, Calif., Nov. 26, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
Nature Communications paper offers pivotal new information about how the virus interacts with and evades therapeutics, as well as new clues to its role in cancer development. New
- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome - LA JOLLA, Calif.,
LA JOLLA, Calif., Nov. 6, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated - LA JOLLA, Calif., Nov.
LA JOLLA, Calif., Nov. 3, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
CARLSBAD, Calif., Nov. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- A poem in which the author retracts something said in an earlier poem.